Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | GLA | P06280 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30691642 | 0.83 | VCP (0.32) | ALDH1A1LMNAMAPT | |
| SCHEMBL30691590 | 0.71 | NQO2 (0.31) | ALDH1A1 | |
| SCHEMBL30691701 | 0.70 | — | — | |
| SCHEMBL30691702 | 0.69 | — | — | |
| SCHEMBL22230729 | 0.63 | ALDH1A1 (0.37) | ALDH1A1MEN1MAPTKMT2A | |
| SCHEMBL30785987 | 0.63 | ALDH1A1 (0.37) | ALDH1A1MEN1MAPTKMT2A | |
| SCHEMBL12689080 | 0.63 | ALDH1A1 (0.38) | ALDH1A1MEN1LMNAMAPTKMT2A | |
| SCHEMBL8755437 | 0.60 | S1PR4 (0.57) | ALDH1A1MEN1MAPTKMT2A | |
| SCHEMBL20642467 | 0.59 | DHFR (0.36) | ALDH1A1LMNAL3MBTL1 | |
| SCHEMBL4502676 | 0.58 | ALDH1A1 (0.39) | ALDH1A1MEN1MAPTKMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119997954-A | Compounds for the treatment of spinocerebellar ataxia type 3 | PTC医疗公司 | 2025-05-13 | — | — | CN | disclosed |
| EP-4543444-A1 | COMPOUNDS FOR TREATING SPINOCEREBELLAR ATAXIA TYPE 3 | PTC Therapeutics, Inc. (US) | 2025-04-30 | — | — | EP | disclosed |
| WO-2023250316-A1 | COMPOUNDS FOR TREATING SPINOCEREBELLAR ATAXIA TYPE 3 | PTC THERAPEUTICS, INC. (US) | 2023-12-28 | — | — | WO | disclosed |